Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNTG 
Centogene B V (CNTG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CNTG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.52
1 Year Target Price $1.52
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.69% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.43M USD | Price to earnings Ratio - | 1Y Target Price 1.52 |
Price to earnings Ratio - | 1Y Target Price 1.52 | ||
Volume (30-day avg) 1 | Beta -0.67 | 52 Weeks Range 0.04 - 0.55 | Updated Date 07/6/2025 |
52 Weeks Range 0.04 - 0.55 | Updated Date 07/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.21% | Operating Margin (TTM) -63.29% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) -1375.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 76915418 | Price to Sales(TTM) 0.06 |
Enterprise Value 76915418 | Price to Sales(TTM) 0.06 | ||
Enterprise Value to Revenue 1.35 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 29000100 | Shares Floating 11780726 |
Shares Outstanding 29000100 | Shares Floating 11780726 | ||
Percent Insiders 4.57 | Percent Institutions 66.89 |
Upturn AI SWOT
Centogene B V
Company Overview
History and Background
Centogene B.V. was founded in 2006 and is based in Rostock, Germany. It started as a spin-off from the University of Rostock. The company focuses on rare disease diagnostics and has expanded to offer broader genetic testing services over time, becoming a global leader in the field.
Core Business Areas
- Diagnostics: Genetic testing services for rare diseases, including sequencing and interpretation of genetic data.
- Pharmaceutical Solutions: Partnerships with pharmaceutical companies to support drug development, including patient identification and biomarker discovery.
- Data Services: Utilizing a proprietary biodata platform to provide insights into rare diseases and genetic variants.
Leadership and Structure
The leadership team includes experienced executives in diagnostics and biotechnology. The organizational structure involves various departments, including diagnostics, R&D, and commercial operations. Andria Lisa Williams serves as the CEO and Mahesh Chhatre as the CFO.
Top Products and Market Share
Key Offerings
- Whole Exome Sequencing (WES): Comprehensive genetic testing to identify mutations across the exome. Centogene doesn't specifically publish market share, but they are considered a key player in rare disease diagnostics. Competitors include Invitae (NVTA), and Quest Diagnostics (DGX).
- Whole Genome Sequencing (WGS): Complete sequencing of an individual's genome, providing the most comprehensive genetic information. Competitors include Illumina (ILMN) and Exact Sciences (EXAS).
- Biomarker Discovery: Partnering with pharmaceutical companies to identify and validate biomarkers for drug development. Competitors include LabCorp (LH) and Charles River Laboratories (CRL).
Market Dynamics
Industry Overview
The genetic testing market is experiencing rapid growth due to advancements in sequencing technologies and increasing awareness of genetic diseases. The rare disease segment is particularly attractive, driven by unmet medical needs and Orphan Drug regulations.
Positioning
Centogene is positioned as a leading specialist in rare disease diagnostics. Its competitive advantages include its extensive biodata platform and its partnerships with pharmaceutical companies.
Total Addressable Market (TAM)
The global genetic testing market is estimated to reach hundreds of billions of dollars. Centogene is positioned within the rare disease diagnostics subset of this TAM, which is expected to grow substantially.
Upturn SWOT Analysis
Strengths
- Proprietary biodata platform
- Expertise in rare disease diagnostics
- Established partnerships with pharmaceutical companies
- Global presence
Weaknesses
- Reliance on specific markets
- Historically, profitability has been difficult to achieve
- Intense competition in the genetic testing market
- Regulatory hurdles
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests
- Increasing partnerships with pharmaceutical companies
- Leveraging AI for data analysis
Threats
- Increased competition from larger genetic testing companies
- Changes in regulatory landscape
- Reimbursement pressures from healthcare payers
- Economic downturns
Competitors and Market Share
Key Competitors
- NVTA
- DGX
- ILMN
- EXAS
- LH
- CRL
Competitive Landscape
Centogene had a focused approach in rare diseases diagnostics. However, competitors have significantly larger resources and broader market coverage.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth was primarily driven by increased demand for genetic testing and expansion into new markets.
Future Projections: Future projections are unavailable following delisting. Prior projections anticipated growth based on increased adoption of genomic medicine.
Recent Initiatives: Recent initiatives included partnerships with pharmaceutical companies for drug development and investments in its biodata platform.
Summary
Centogene focused on rare disease diagnostics, leveraging its biodata platform and partnerships. However, it faced challenges in achieving profitability and was ultimately delisted. The company needs to improve financial stability and address competitive pressures. The company had a competitive advantage on data but needs to ensure it stays ahead of competitors. Investors should be wary about the company's future due to delisting and past financial struggles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (prior to delisting)
- Market research reports
- Analyst reports
Disclaimers:
Financial data may be outdated due to delisting. Market share figures are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centogene B V
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-11-07 | CEO & Member of Management Board Ms. Kim Stratton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 384 | Website https://www.centogene.com |
Full time employees 384 | Website https://www.centogene.com | ||
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.